ERBB3 and neoplasm: To evaluate their in vitro drug-delivery capacity, we exposed each NBP to HER3+ tumour cells (mouse TNBC 4T1) and HER3− non-tumour cells (mouse fibroblast NIH3T3) in culture and compared each to untargeted and drug-free controls.